Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.67 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.67 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 3/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17943651 | 0.90 | AGTR1 (0.62) | AGTR1AGTR2GP6 | |
| SCHEMBL18003201 | 0.90 | AGTR1 (0.61) | AGTR1AGTR2GP6 | |
| SCHEMBL8638896 | 0.88 | AGTR1 (0.58) | AGTR1AGTR2GP6PDE4APDE4B | |
| SCHEMBL28517678 | 0.87 | AGTR1 (0.59) | AGTR1AGTR2GP6 | |
| SCHEMBL4639444 | 0.87 | AGTR1 (0.59) | AGTR1AGTR2GP6 | |
| SCHEMBL8568897 | 0.87 | AGTR1 (0.59) | AGTR1AGTR2GP6 | |
| SCHEMBL9423362 | 0.87 | AGTR1 (0.65) | AGTR1AGTR2GP6TLR7 | |
| SCHEMBL7828008 | 0.87 | AGTR1 (0.64) | AGTR1AGTR2GP6 | |
| SCHEMBL28517096 | 0.86 | AGTR1 (0.56) | AGTR1AGTR2GP6 | |
| SCHEMBL9152560 | 0.85 | AGTR1 (0.62) | AGTR1AGTR2GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| CN-101646653-A | Fused ring compounds as partial agonists of ppar-gamma | TAKEDA PHARMACEUTICAL JP | 2010-02-10 | — | — | CN | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | AGTR1 173/4885AGTR2 258/4885GP6 3690/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | AGTR1 119/4885AGTR2 176/4885GP6 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.